Biodesix (BDSX)
NASDAQ:BDSX
Want to see BDSX full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.92Last Year’s EPS
-1.6Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a clear positive trajectory: robust top-line growth (42% YoY), meaningful margin expansion (300 bps YoY), doubling of development services revenue, and improved profitability metrics (net loss and adjusted EBITDA both materially improved). Management raised full-year guidance and detailed a repeatable commercial expansion plan (salesforce growth, primary care adoption) supported by strong clinical evidence (large validation study). Remaining negatives are that the company is not yet profitable, operating expenses exceeded Q1 revenue due to planned commercial investment, development services revenue showed some timing-driven variability, and operational/logistics risks (weather/FedEx) and one-time items introduce some quarter-to-quarter noise. On balance, the highlights significantly outweigh the lowlights, indicating constructive momentum toward sustained growth and eventual profitability.Company Guidance
Strong Revenue Growth
Total revenue of $25.6M in Q1 2026, up 42% year-over-year; full-year 2026 revenue guidance raised to $108M–$114M (midpoint ≈ 25% growth vs. 2025).
Diagnostic Testing Momentum
Diagnostic testing revenue of $22.3M, up 37% year-over-year; test volumes ~17.8k, up 29% year-over-year; primary care now represents 15% of total tests, reflecting broader adoption.
Development Services Acceleration
Development services revenue nearly doubled to $3.3M (up 99% year-over-year); contracted backlog of approximately $10.4M entering the quarter, indicating sustained demand.
Margin Expansion and Operational Efficiency
Gross margin 84% GAAP (82% excluding a one-time $0.4M tax recovery), a 300 basis-point improvement year-over-year, driven by scale, improved ASPs, and lower cost per test.
Improved Profitability Trajectory
Net loss improved to $7.8M (30% improvement YoY); adjusted EBITDA loss of $4.1M (35% improvement YoY), reflecting operating leverage gains and progress toward sustained profitability.
Strengthened Liquidity
Ending unrestricted cash and cash equivalents of $25.6M, a 35% increase versus the prior quarter, including $16.8M of at-the-market net proceeds raised during Q1.
Clinical Evidence and Market Recognition
Published largest lung nodule biomarker clinical validation study (>1.1k patients) demonstrating high specificity across nodule sizes; multiple presentations (AACR) and upcoming data at ASCO; recognized as a top workplace for the third consecutive year.
Commercial Expansion Plan
Average of 100 sales representatives in the field in Q1 with planned cadence of ~6 new reps per quarter through 2026 to expand coverage and drive volume growth; sales productivity expected to improve as cohorts mature.
BDSX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BDSX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 04, 2026 | $11.27 | $14.94 | +32.56% |
Feb 26, 2026 | $14.22 | $15.33 | +7.81% |
Nov 03, 2025 | $6.34 | $7.60 | +19.87% |
Aug 07, 2025 | $8.94 | $8.01 | -10.40% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biodesix (BDSX) report earnings?
Biodesix (BDSX) is schdueled to report earning on Aug 12, 2026, After Close (Confirmed).
What is Biodesix (BDSX) earnings time?
Biodesix (BDSX) earnings time is at Aug 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BDSX EPS forecast?
BDSX EPS forecast for the fiscal quarter 2026 (Q2) is -0.92.